CellaVision Valuation
Is CEVI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CEVI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CEVI (SEK270) is trading below our estimate of fair value (SEK363.67)
Significantly Below Fair Value: CEVI is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CEVI?
Other financial metrics that can be useful for relative valuation.
What is CEVI's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 6.44b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 8.8x |
Enterprise Value/EBITDA | 30.9x |
PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does CEVI's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 44.6x | ||
ELOS B Elos Medtech | 104.3x | n/a | SEK 5.7b |
ARJO B Arjo | 22.8x | 18.6% | SEK 11.7b |
SUS Surgical Science Sweden | 29.5x | 32.5% | SEK 5.8b |
EKTA B Elekta | 21.7x | 17.7% | SEK 24.6b |
CEVI CellaVision | 44.4x | 24.1% | SEK 6.4b |
Price-To-Earnings vs Peers: CEVI is good value based on its Price-To-Earnings Ratio (44.4x) compared to the peer average (44.6x).
Price to Earnings Ratio vs Industry
How does CEVI's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: CEVI is expensive based on its Price-To-Earnings Ratio (44.4x) compared to the European Medical Equipment industry average (30.4x).
Price to Earnings Ratio vs Fair Ratio
What is CEVI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 44.4x |
Fair PE Ratio | 26.6x |
Price-To-Earnings vs Fair Ratio: CEVI is expensive based on its Price-To-Earnings Ratio (44.4x) compared to the estimated Fair Price-To-Earnings Ratio (26.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | SEK 270.00 | SEK 256.75 -4.9% | 8.7% | SEK 295.00 | SEK 240.00 | n/a | 4 |
Aug ’25 | SEK 250.00 | SEK 255.50 +2.2% | 9.2% | SEK 295.00 | SEK 235.00 | n/a | 4 |
Jul ’25 | SEK 247.50 | SEK 256.25 +3.5% | 10.0% | SEK 300.00 | SEK 235.00 | n/a | 4 |
Jun ’25 | SEK 262.00 | SEK 257.50 -1.7% | 9.6% | SEK 300.00 | SEK 240.00 | n/a | 4 |
May ’25 | SEK 225.50 | SEK 257.50 +14.2% | 9.6% | SEK 300.00 | SEK 240.00 | n/a | 4 |
Apr ’25 | SEK 239.00 | SEK 256.25 +7.2% | 9.9% | SEK 300.00 | SEK 240.00 | n/a | 4 |
Mar ’25 | SEK 256.00 | SEK 256.25 +0.1% | 9.9% | SEK 300.00 | SEK 240.00 | n/a | 4 |
Feb ’25 | SEK 206.50 | SEK 204.25 -1.1% | 12.3% | SEK 230.00 | SEK 165.00 | n/a | 4 |
Jan ’25 | SEK 212.00 | SEK 191.75 -9.6% | 11.2% | SEK 222.00 | SEK 165.00 | n/a | 4 |
Dec ’24 | SEK 176.40 | SEK 191.75 +8.7% | 11.2% | SEK 222.00 | SEK 165.00 | n/a | 4 |
Nov ’24 | SEK 139.80 | SEK 200.50 +43.4% | 7.4% | SEK 222.00 | SEK 180.00 | n/a | 4 |
Oct ’24 | SEK 153.60 | SEK 220.00 +43.2% | 8.5% | SEK 250.00 | SEK 200.00 | n/a | 4 |
Sep ’24 | SEK 198.00 | SEK 220.00 +11.1% | 8.5% | SEK 250.00 | SEK 200.00 | SEK 263.50 | 4 |
Aug ’24 | SEK 218.50 | SEK 220.00 +0.7% | 8.5% | SEK 250.00 | SEK 200.00 | SEK 250.00 | 4 |
Jul ’24 | SEK 183.60 | SEK 197.50 +7.6% | 11.9% | SEK 220.00 | SEK 165.00 | SEK 247.50 | 4 |
Jun ’24 | SEK 188.80 | SEK 197.50 +4.6% | 11.9% | SEK 220.00 | SEK 165.00 | SEK 262.00 | 4 |
May ’24 | SEK 175.00 | SEK 222.50 +27.1% | 20.1% | SEK 280.00 | SEK 160.00 | SEK 225.50 | 4 |
Apr ’24 | SEK 185.00 | SEK 247.50 +33.8% | 11.1% | SEK 280.00 | SEK 205.00 | SEK 239.00 | 4 |
Mar ’24 | SEK 201.50 | SEK 250.00 +24.1% | 9.5% | SEK 280.00 | SEK 215.00 | SEK 256.00 | 4 |
Feb ’24 | SEK 252.50 | SEK 260.00 +3.0% | 4.7% | SEK 275.00 | SEK 245.00 | SEK 206.50 | 3 |
Jan ’24 | SEK 229.00 | SEK 260.00 +13.5% | 4.7% | SEK 275.00 | SEK 245.00 | SEK 212.00 | 3 |
Dec ’23 | SEK 225.50 | SEK 252.50 +12.0% | 3.0% | SEK 260.00 | SEK 245.00 | SEK 176.40 | 2 |
Nov ’23 | SEK 204.50 | SEK 252.50 +23.5% | 3.0% | SEK 260.00 | SEK 245.00 | SEK 139.80 | 2 |
Oct ’23 | SEK 254.50 | SEK 307.50 +20.8% | 8.9% | SEK 335.00 | SEK 280.00 | SEK 153.60 | 2 |
Sep ’23 | SEK 323.50 | SEK 360.00 +11.3% | 6.9% | SEK 385.00 | SEK 335.00 | SEK 198.00 | 2 |
Analyst Forecast: Target price is lower than the current share price.